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Abstract
Purpose An improved understanding of RCC immunology should shed further light on RCC tumor biology. Our objective 
was to study to what extent serum levels of the IL-6 family of cytokines at diagnosis were relevant to survival.
Methods A total of 118 consecutively patients with RCC, in which the tumor was surgically removed at Haukeland University 
Hospital during the period from 2007 to 2010, were included. The patients were followed-up for 10 years. The morning before 
surgery blood was sampled and serum frozen, with levels of IL-6, IL-27, IL-31, OSM, CNTF, IL-6Rα and gp130 determined.
Results Among patients with the highest quartile of IL-6 (> 8 pg/ml) (n = 29), six of nine who had metastasis at diagnosis 
had such high IL-6 values. Among presumed radically treated patients, a high IL-6 and IL-27 strongly predicted recurrence. 
In particular, the predictions among patients with large (diameter > 7 cm) tumors were excellent regarding both IL-6 and 
IL-27 values. High gp130 serum levels predicted an overall survival (OS) among RCC patients with large tumors. Patients 
with a high IL-6 exhibited a strong expression of IL-6 in endothelial- and vascular smooth muscle cells. Moreover, the level 
of intra-tumoral CD3-positive cells predicted survival.
Conclusions IL-6 and IL-27 seem to play a role in RCC biology. IL-6 enables the pinpointing of metastatic condition at 
diagnosis, as well as together with IL-27, the predicting of survival and recurrence. Endothelial cells and vascular smooth 
muscle cells are both suggested as important sources of IL-6.
Keywords IL-6 · IL-27 · gp130 · Survival · Recurrence · Renal cell carcinoma
Introduction
Cancer diseases are major global killers of humans [1]; thus, 
there is an urgent need to better understand these diseases. 
It is generally accepted that carcinomas are caused by 
somatic DNA mutations with a consequent dysregulation 
of the affected cells. Furthermore, it has been known that 
carcinomas are not only built by actual carcinoma cells, 
but also, e.g., by intra-tumor immune cells. Biological 
information from carcinomas is collected with a biopsy, or 
from a resected tumor, both of which are instant pictures 
of a long-term ongoing process. One important source of 
tumor biology knowledge is serum samples, of which tumor-
associated secretory interleukins/cytokines contribute, with 
the study of this cytokine reservoir in cancer patients being 
the primary goal of this study. One primary validity criteria 
of all cancer studies is the association to prognosis, so we 
will therefore presently use survival as our readout variable.
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Renal cell cancer (RCC) is the ninth  most common 
cancer in men and 14th most common cancer in women. 
In 2018, 175,098 deaths by RCC were estimated, making 
it the 14th most common cause of global cancer deaths [2]. 
RCC represents one of the major immunogenic carcinomas 
[3]. Over the last few years, biological therapy has gained 
importance as a treatment for metastatic RCC, mostly by 
VEGF blockage [4]. Recently, modern immune therapy has 
also been introduced [5].
IL-6 is a cytokine produced by, e.g., macrophages, Th2 
cells, B cells, astrocytes, endothelial cells, adipocytes and 
some tumor cells [6]. IL-6 has been shown to promote 
tumor proliferation, metastases and symptoms of cachexia 
[6]. In a review paper, the IL-6 serum level at diagnosis 
was significantly correlated to survival in 82/101 series, 
comprising 9917 out of 11,583 patients with 23 different 
cancer types [7].
IL-6 regulates inflammation by two main pathways: The 
classic signaling, in which it binds to a membrane-bound 
IL-6α receptor expressed in only a few cell types and then 
secondarily to membrane-bound gp130 (signal transducing 
receptor glycoprotein 130 kDa) present in many cells [8]. 
The trans signaling IL-6 binds to membrane gp130 through 
a primary binding to serum IL-6Rα [9]. The classical 
signaling stimulates the regenerative and anti-inflammatory 
activity, whereas trans signaling has more general 
stimulatory effects [9]. When IL-6/IL-6Rα binds to gp130, 
three signaling pathways may be activated: JAK-STAT, Ras-
ERK cascade or P13K-Akt signaling. Through all three ways 
of trans signaling, IL-6 promotes the growth of cancer cells, 
whereas STAT3 IL-6 also promotes tumor cells’ ability to 
escape apoptosis [10]. On the other hand, soluble gp130 
receptor serves as a decoy receptor that inhibits the function 
of IL-6/IL-6Rα complex [11].
Several other cytokines also share the use of gp130 
subunit receptor. These cytokines are collectively named the 
IL-6 family of cytokines [8, 12], which has several members, 
including IL-11, IL-27, IL-31, ciliary neurotrophic factor 
(CNTF), leukemia inhibitory factor (LIF), oncostatin M 
(OSM) and cardiotrophin-like cytokine factor 1 (CLC) [13]. 
The receptor signaling complexes for IL-6 and IL-11 contain 
a gp130 homodimer, whereas other family members signal 
via a heterodimeric receptor complex containing gp130 [13].
IL-6 has been shown to be secreted from RCC cells 
exposed to hypoxia, and hypothesized to contribute to RCC 
invasion and the development of metastasis [14–16]. In RCC 
serum IL-6 levels have been associated with extended tumor 
stage, grade and metastatic progression [16].
Regarding other IL-6 family cytokines, Pu et al. [17] 
showed that two polymorphisms in the IL-27 gene were 
associated with an increased risk for RCC. IL-27 acts 
through a receptor consisting of IL-27Rα and gp130, which 
mediates signaling mostly through STAT1 and STAT3, 
though similarly to IL-6. IL27-Rα is present on B, T and 
NK cells, neutrophils, monocytes and mast cells, as well as 
in lower levels in macrophages, hepatocytes, keratinocytes 
and endothelial cells [18]. IL-27 has demonstrated antitumor 
activity in prostate cancer, multiple myeloma, non-small cell 
lung cancer and ovarian cancer cell lines [18]. In contrast, 
high serum levels of IL-27 in breast and gastroesophageal 
cancer are correlated with advanced stage [18].
Tumor diameter, measured by CT prior to surgery, is a 
strong indicator for survival [19]. Most RCC-caused deaths 
occur in patients with tumors > 7 cm in diameter. Hence, we 
have aimed in particular at studying large RCC tumors as to 
evidence for cytokine involvement.
It is also of interest to study tumor tissue, both for 
the source of secretion and as a potential target [20]. We 
have therefore studied the level of macrophages and T 
lymphocytes in and around tumors, as well as IL-6 and IL-6 
receptor levels on endothelial cells, macrophages and T 
lymphocytes, both in and adjacent to the tumors in patients 
with a high serum IL-6.
In this study, we have aimed at investigating whether the 
IL-6 family of cytokine members and pertinent cytokines 
receptors levels, both in serum preoperatively and in tumor 
tissue, relate to RCC biology by studying the prognostic 
value of these cytokine/receptor levels at diagnosis.
Material and methods
Patients
From the kidney cancer database at Haukeland University 
Hospital, we identified 159 consecutive patients treated with 
nephron sparing surgery (NSS), a radical nephrectomy (RN) 
or a cyto-reductive nephrectomy at our institution between 
January 1, 2007 and March 31, 2010. All histological 
subtypes and stages were included. For IL-6 analyses, 118 
patients with appropriate blood samples were available, 
while for the other cytokine analyses 97 patients were 
available. Attrition analyses revealed no difference in regard 
to descriptive statistics between individuals registered in the 
database who had blood samples bio-banked and those who 
did not. Most patients were male [n = 88 (75%)], the mean 
age was 63 years (median 64, IQR 55–73) and the mean 
tumor size was 6.3 cm (median 5.3, interquartile range IQR 
3.7–8.7). A radical nephrectomy was performed in 66% 
(n = 75) of the patients.
All patients were followed-up to January 18, 
2018/10  years or time of death, and the information 
registered. The follow-up flow chart at Haukeland University 
Hospital, which is based on Leibovich score (stage, lymph 
nodes, tumor size, nuclear grade and tumor necrosis) has 
been previously reported [21]. The mean observation time 
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was 99 (median 105, IQR 95–120) months. During the 
observation period, 20 patients died from RCC, while 19 
patients died from other causes. A total of 14 patients (12%), 
presumed radically treated, developed metastases during the 
follow-up period. Our institutional Follow-up regime has 
been described in detail by our group [22]. The Regional 
Committee for Medical Research Ethics in Western Norway 
(78/05), the study and the Norwegian Social Science Data 
Services all approved the database. All patients signed 
informed consent forms at inclusion.
Tumor assessment
Patients were staged according to the 2009 TNM 
classification system, and the tumor histology was graded 
according to the Fuhrman nuclear criteria [23].
Laboratory cytokine assessment
Preoperative blood samples were drawn on the morning 
of the surgery, and serum was frozen at − 80/150 °C until 
analysis. Serum IL-6 was detected using the Luminex 
immune-bead technology and a high-sensitivity kit 
(Invitrogen/Biosource, Carlsbad, CA, USA). In short, 
antibody-coupled beads were incubated with serum and 
incubated with a biotinylated detection antibody, before 
finally being incubated with streptavidin–phycoerythrin. 
Samples were then read by the Luminex’s laser-based 
fluorescent analytical test instrument  Luminex® 100™ 
(Luminex Corporation Austin, TX, USA). Gp130, IL-27, 
IL-31, IL-6Rα, OSM, and CNTF measured with the same 
method: Human Premixed Multi-Analyte Kit from R&D 
system, and the latter by the use of the Milliplex map kit 
Human Pituitary Magnetic Bead Panel 1 (Millipore, Sigma-
Aldrich, Oslo, Norway).
Immunohistological assessment
Tumor tissue from patients with the highest IL-6 serum 
levels (n = 29) was investigated, with one representative 
block selected from each case. The selected slide contained 
both tumor tissue corresponding to the tumor ISUP grade 
and an area bordering on and comprising kidney parenchyma 
(interphase zone). An experienced uropathologist classified 
all the RCCs based on hematoxylin and eosin-stained 
sections.
Immunohistochemistry was performed using the 
automated benchmark ultra-system (Ventana-Diagnostics 
Roche). Four-micrometer sections from the formalin-
fixed paraffin embedded (FFPE) tissue blocks were 
de-paraffinized and rehydrated, while antigen retrieval 
was done by conditioning the cells in a TRIS-based buffer 
(CC1, Ventana) and heating. After endogenous peroxidase 
blocking, the slides were incubated with the primary 
antibodies. Detection was performed by  OptiView® (OV) 
and  UltraView® (UV) DAB detection kits (Ventana Medical 
Systems), with hematoxylin used as a counterstain. Human 
spleen and lymph node sections were used as positive 
controls, while for negative controls, primary antibodies 
were omitted (Supplementary Table 1).
The whole tumor area in the slide was examined and the 
subjective impression of density and number of positive 
cells were scored semi-quantitatively and subjectively. 
The proportion of IL-6 and IL6R-positive tumor cells were 
scored as “no positive tumor cells” (0), “less than 10% 
positive tumor cells” (1 +), “10–50% positive tumor cells” 
(2 +), or “more than 50% positive tumor cells” (3 +). For 
CD3, CD68 and FOXP3, 1 + means slight and scattered 
infiltration, 2 + moderate infiltration and 3 + the dense 
infiltration of positive cells in more than 50% of the area.
Statistical analysis
Comparisons between groups were performed with cross-
tables and exact Chi-square test, Mann–Whitney U test 
and T test for categorical, ordinal and continuous data, 
respectively. A patient’s serum levels of IL-6 ≥ 8 pg/ml (the 
uppermost quartile), and of IL-27 for the uppermost quartile, 
were defined as high. The multiple logistic regression 
models were performed in a backward likelihood ratio (LR) 
test manner without a pre-selection of the variables.
Kaplan–Meier analyses were used to estimate DSS and 
recurrence-free survival (RFS). For a survival comparison 
between different groups, a log rank test was used. A Cox 
proportional hazard model was used to determine DSS 
and RFS predictions after adjusting for other variables 
affecting survival in univariate analyses. Correlations 
between variables were calculated using Kendall analyses, 
while ROC curves were used to calculate predictive value, 
sensitivity and specificity of IL-6/IL-27 as to recurrence. 
For all statistical analyses, a p value of less than 0.05 was 
considered statistically significant, and calculations were 
performed using the  IBM®  SPSS® Statistics software 
(Release 24.0).
Results
IL‑6 family cytokines versus tumor characteristics 
in patients presumed radically treated
The patients (n = 109) were divided into two groups, 
those with a low (IL-6 < 8 pg/ml) vs. high (IL-6 ≥ 8 pg/
ml) IL-6 values at diagnosis. The groups did not differ in 
RCC subtype, tumor size, pathological stage, nuclear grade 
or other known predictive factors. Histological positive 
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margins (p = 0.05) and pT stage (p = 0.054) differences 
were borderline differentiating between the patient groups 
(Supplementary Table 2). Immunohistochemistry was done 
in patients with high Il-6 in serum (Fig. 1).
IL‑6 family cytokines and soluble receptors 
recurrence prediction
IL-6 levels predicted recurrence, both by Kaplan–Meier 
survival analysis (p = 0.001) (Fig. 2a) and utilizing a Cox 
multivariate regression analysis, with age, gender and 
tumor size additionally included as covariates (HR 7.13, CI 
2.23–22.8; p = 0.001) (Table 1). IL-27 showed a significant 
prediction of recurrence, analyzed by Kaplan–Meier analysis 
(p = 0.026) (Fig.  2b) and multivariate Cox regression 
analysis, with covariates being age, gender and tumor size 
(HR 6.89; CI 1.56–30.4; p = 0.011) (Table 1).
If both IL-6 and IL-27 were included to one Cox 
multivariate regression analysis, the recurrence of those 
presumably cured was predicted by IL-6 (p = 0.004), but 
not regarding IL-27 (p = 0.082) (Table 2).
If the patients were grouped by tumor size (± 7 cm) and 
studied by Kaplan–Meier analyses, both IL-6 (p = 0.014) 
(Fig. 2c) and IL-27 (p = 0.001) (Fig. 2d) predicted recurrence 
among patients with large tumors (diameter > 7.0  cm). 
Regarding gp130 levels there was not a statistic significance 
(p = 0.082) (Fig. 2e).
IL‑6 family cytokines and soluble receptors vs. DSS
IL-6 predicted DSS in both Kaplan–Meier analysis 
(p < 0.001) (Fig. 3a) and multivariate regression analysis, 
including gender, age and tumor size (HR 4.82; CI 
1.96–11.86; p = 0.001) (Table 1). In regard to IL-27, there 
was a borderline DSS prediction in the Kaplan–Meier 
analysis (p = 0.052) (Fig. 3b).
If both IL-6 and IL-27 were included in one Cox 
multivariate regression analysis for DSS, only IL-6 
levels were predicted (HR 20.7; CI 2.6–44.4; p = 0.001) 
(Table 2).
IL-6, gp130 and IL-6Rα were included to one DSS 
multivariate analysis that also included gender, age 
and tumor size in one Cox regression survival model. 
Subsequently, IL-6 (p < 0.001) and IL-6Rα (p = 0.02), but 
not gp130, showed survival prediction (Table 2).
If analyzed by tumor size, patients with a tumor 
diameter from a 4 to 7 cm IL-6 level predicted survival 
by Kaplan–Meier analysis (p = 0.001) (Fig. 3c). The same 
was the case with large tumors (tumor diameter > 7.0 cm) 
(p = 0.02) (Fig. 3g). When IL-27 levels were analyzed by 
size, it was determined that a survival prediction was found 
among the patients with large tumors (diameter > 7 cm) 
(p = 0.025) (Fig.  3d). Including only tumors > 7  cm, 
s-gp130 levels exhibited no survival prediction (p = 0.09) 
Fig. 1  a The panels show low 
(left) and high (right) scores 
with tumor area CD3 staining 
lymphocytes. b The panels 
show renal tissue outside the 
tumor: to the left small arteries 
showing IL-6 positivity, 
and to the right interlobular 
artery showing a strong IL-6 
expression in medial smooth 
muscle cells
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(Fig. 3e). The same was the case with the soluble sIL-6Rα 
levels (p = 0.08) (Fig. 3f).
IL‑6 family cytokines and soluble receptors vs. 
overall survival (OS) with all patients included
In Kaplan–Meier analysis, IL-6 values predicted OS 
(p = 0.001) (Fig. 4a). In a Cox multivariate survival analysis, 
including the gender, age and tumor size of the patient, a 
significant survival prediction was still determined (HR 
2.99; CI 1.5–5.81; p = 0.002) (Table  1). IL-27 showed 
no survival prediction with a Kaplan–Meier approach 
(p = 0.066) (Fig. 4b). Regarding Cox multivariate regression 
analysis (HR 1.98; CI 0.86–4.57; p = 0.11) (Table 1), OS was 
not predicted. The model was tested and was stable for HR 
with regard to the IL-6 and IL-27 groups.
Fig. 2  Kaplan–Meier recurrence curves from IL-6 and some family 
members, as analyzed by Luminex in the serum of assumed radically 
treated renal cell carcinoma (RCC) patients, sampled prior to surgery. 
The blue line represents a low value, whereas the red dotted line 
indicates a high value. Differences between the groups are examined 
in log-rank tests and presented with p values. a IL-6 recurrence 
prediction among 109 RCC patients (low (< 8  pg/ml): n = 86 and 
high (≥ 8 pg/ml): n = 23). b IL-27 prediction of recurrence in 91 RCC 
patients (low: n = 69 and high: n = 22). c–e Recurrence prediction of 
IL-6, IL-27, and gp130 in patients with large (> 7 cm) RCC tumors 
(low: three lower quartiles)/high: highest quartile). c IL-6: n = 35 
(25/10). d IL-27: n = 26 (20/6). e gp130: n = 26 (22/4)
Table 1  Recurrence and 
survival predictions from IL-6 
and IL-27 in Cox regression 
analyses
HR hazard ratio, CI confidence interval
Univariate Multivariate including age, gender and 
tumor size
HR 95% CI p value HR 95% CI p value
Lower Upper Lower Upper
Recurrence in presumed cured patients
 IL-6, n = 109 4.99 1.74 14.3 0.003 7.13 2.23 22.8 0.001
 IL-27, n = 91 3.77 1.08 13.2 0.038 6.89 1.56 30.4 0.011
Disease-specific survival in all included patients
 IL-6, n = 118 4.97 2.06 12.0 < 0.001 4.82 1.96 11.9 0.001
 IL-27, n = 97 2.82 0.95 8.40 0.062 3.02 0.94 9.64 0.063
Overall survival of all included patients
 IL-6, n = 118 2.81 1.46 5.40 0.002 2.99 1.54 5.81 0.001
 IL-27, n = 97 2.05 0.94 4.50 0.072 1.98 0.86 4.57 0.108
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If the patients were grouped by tumor size, the IL-6 
values in particular predicted survival among patients 
with medium-sized tumors (tumor diameter from 4 to 
7 cm) (p = 0.018) (Fig. 4c), but not statistically significant 
(p = 0.063) among large tumors (Fig. 4e). If gp130 levels 
were studied in patients with large tumors only, a high gp130 
level predicted a lower survival (p = 0.001) (Fig. 4d).
Outcome dependent on IL‑6 levels at the individual 
patient level
We detected IL-6 > 8 pg/ml in 29 patients: six of those 
with metastasis at the time of diagnosis, with seven of the 
remaining 23 patients presumed radically treated having 
had a subsequent RCC recurrence. Of those patients with 
a low IL-6 who died, or developed recurrent RCC disease 
(n = 10), only one had a RCC tumor < 7 cm at diagnosis. 
Five of the 10 patients with a high IL-6 who were still 
alive and without disease recurrence at the study closure, 
Table 2  Outcome predictions 
from combined IL-6 and family 
cytokine members in Cox 
regression analyses
HR hazard ratio, CI confidence interval
Multivariate (only cytokine/receptor 
combined)
Multivariate including age, gender and 
tumor size
HR 95% CI p value HR 95% CI p value
Lower Upper Lower Upper
Recurrence in radically treated patients (n = 91)
 IL-6 6.64 1.80 24.4 0.004 25.5 3.04 213.4 0.003
 IL-27 3.10 0.87 11.1 0.082 1.54 0.20 11.7 0.675
Disease-specific survival (n = 97)
 IL-6 7.47 2.26 24.7 0.001 10.8 2.62 44.4 0.003
 IL-27 1.98 0.65 6.00 0.227 0.85 0.22 3.30 0.813
 IL-6 10.1 3.07 33.4 < 0.001 20.7 5.25 81.4 < 0.001
 IL-6Rα 0.17 0.021 1.31 0.089 0.068 0.007 0.66 0.020
 gp130 1.11 0.24 5.12 0.889 2.64 0.45 15.4 0.281
Fig. 3  Kaplan–Meier curves demonstrating disease-specific 
survival (DSS) prediction from IL-6, as well as related cytokines 
and receptors in pre-treatment RCC blood samples collected before 
surgical treatment. Analytes were measured simultaneously by 
Luminex technology. Low values are shown with a blue continuous 
line, and high values in red dotted lines. In addition, the graphs 
comprise p values from log-rank tests. a IL-6 DSS prediction among 
118 RCC patients (low (< 8  pg/ml): n = 89 and high (≥ 8  pg/ml): 
n = 29). b IL-27 prediction of DSS in 97 RCC patients (low: n = 73 
and high: n = 24). c and g DSS prediction from IL-6 in medium-
sized (4.1–7 cm, n = 37) and large (> 7 cm, n = 42) RCC tumors. The 
highest quartile is denoted by high (n = 10/14), and the remaining 
values low (n = 27/23). d–f IL-27, gp130 and IL6R alpha prediction 
of DSS in patients harboring a large (> 7  cm) RCC tumor (n = 30). 
Quartiled analytes as above (high: n = 7/4/6 and low: n = 23/26/24)
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Fig. 4  Overall survival (OS) Kaplan–Meier curve predictions from 
IL-6 and the family molecules IL-27 and gp130 by Luminex in serum 
collected before the surgical treatment of RCC patients. The blue 
continuous line visualizes low values (lower quartiles), with the high 
values in the red dotted line. Log-rank test p values are included in 
the separate windows. a IL-6 OS prediction among 118 RCC patients 
(low (< 8  pg/ml): n = 89 and high (≥ 8  pg/ml): n = 29). b IL-27 
prediction of OS in 97 RCC patients (low: n = 73 and high: n = 24). 
c OS prediction from IL-6 in medium-sized [(4.1–7  cm, n = 37), 
n = 42] RCCs. Twenty-seven patients were designated as low, with 10 
patients having a value within the highest quartile. d Prediction of OS 
from quartiled gp130 in RCC patients with a tumor size exceeding 
7  cm (low: n = 26 and high: n = 4). e IL-6 OS prediction in large 
(> 7 cm, n = 42) RCC tumors; 28 high value patients and 14 with a 
low value
Table 3  Description of immunohistochemical analyses, staining assessment and numbers
Patient samples (n = 28) were scored in a semi-quantitative fashion, reviewed by an expert in pathology (LB) and further transformed into 
numeric values for statistical analyses according to the following: +++ = 3, ++ (+) = 2.5, ++ = 2, + (+) = 1.5, + = 1, ± = 0.5, = 0.25, and − = 0.0
a n = 27
– = 0.0 ± = 0.25 ± = 0.5 + = 1.0 + (+) = 1.5 ++ = 2.0 ++ (+) = 2.5 +++ = 3.0
CD3-positive tumor lymphocytes 1 0 5 11 4 2 4 1
CD3-positive lymphocytes in interphase zone 3 0 7 10 2 4 1 1
CD68-positive cells in tumor 0 0 3 7 7 6 5 0
CD68-positive interphase zone cells 14 1 5 5 1 2 0 0
FoxP3 in tumor  lymphocytesa 9 14 2 2 0 0 0 0
FoxP3 in interphase zone  lymphocytesa 9 8 6 3 0 1 0 0
FoxP3 in tumor  cellsa 25 2 0 0 0 0 0 0
IL6 in tumor lymphocytes 18 2 4 4 0 0 0 0
IL6 in interphase zone lymphocytes 16 10 2 0 0 0 0 0
IL6 in tumor cells 5 8 6 4 2 3 0 0
IL6 in vasculature 1 2 1 3 2 6 1 12
IL6 receptor in tumor lymphocytes 5 13 6 1 0 3 0 0
IL6R in interphase zone lymphocytes 3 12 6 5 0 2 0 0
IL6R in tumor cells 1 10 6 7 4 0 0 0
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had either a second primary cancer or an autoimmune 
disease at diagnosis.
Outcome by ROC analyses
Both tumor diameter and IL-6 values predicted DSS and 
recurrence. According to IL-6 for recurrence, estimated 
areas under the curve (AUC) were 0.723 ± 0.075 (p = 0.007) 
and 0.692 ± 0.074 (p = 0.020), employing presumed radically 
treated or all patients, respectively. Regarding IL-27, the 
corresponding AUC results were 0.762 ± 0.080 (p = 0.007) 
and 0.757 ± 0.079 (p = 0.008), respectively (Fig.  5). 
Including only presumed radically treated patients and with 
large tumors (diameter > 7 cm), the AUC were 0.908 ± 0.069 
(p = 0.001) in the case of IL-27, and 0.707 ± 0.098 
(p = 0.048) in the case of IL-6 (Fig. 5).
IL‑6 and IL‑27 prediction of recurrence adjusted 
by Leibovich scores
IL-6 and IL-27 levels were studied by Cox regression 
adjusted by Leibovich scores. The results showed that both 
IL-6 (p = 0.01) and IL-27 (p = 0.014) still predicted survival 
following such an adjustment (Supplementary Table 3).
Patients with high serum IL‑6: outcome compared 
to tumor and tumor border (interphase) tissue 
CD3, CD68, IL‑6 and IL6R‑positive cells determined 
by immunohistochemistry
By immunohistochemistry, we have determined the level of 
CD3, FoxP3, CD68, IL-6 and IL6R-positive cells in tumors 
from patients with high IL-6 serum values (Table 3). The 
following number of patients with at least a 10% (1 +) 
expression on markers denoting cell characteristics were 
found at least at 1 + levels: intra-tumor CD3 + lymphocytes: 
22/28, interphase zone CD3 + lymphocytes: 18/28, 
intra-tumor CD68 + cells: 25/28, interphase zone 
CD68 + cells: 8/28, FoxP3 + intra-tumor lymphocytes: 
2/27, FoxP3 + interphase zone lymphocytes: 4/27 and 
FoxP3 + tumor cells: 0/27. 
Regarding the present IL-6 content of the various tumor-
associated cells, the following were determined: intra-tumor 
lymphocytes: 4/28, interphase zone lymphocytes: 0/28, 
tumor cells 9/28 and most density was seen in vascular cells: 
Fig. 5  ROC recurrence. 
Receiver operating 
characteristic (ROC) curves 
comparing recurrence 
prediction of IL-6, IL-27, and 
CRP in presumed radically 
treated (upper panel, n = 89) 
and all (lower panel, n = 95) 
RCC patients with such values, 
as analyzed in their serum 
ahead of surgical treatment. In 
both cases, 10 were regarded 
as positive. The right column 
shows results in patients with 
a tumor above 7 cm, of which 
nine had a positive annotation. 
The blue continuous line 
represents IL-6, the red dotted 
line is IL-27, and green semi-
hatched line indicated by CRP
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IL6 24/28. In the case of the IL6R, the following numbers 
were denoted: intra-tumor lymphocytes 4/28, interphase 
zone lymphocytes: 7/28 and tumor cells: 11/28.
The cellular derived measurement did not substantially 
correlate to tumor diameter or CRP levels. The various 
above-mentioned variables were also tested regarding 
prognostic value. In particular, the extent of T lymphocytes 
(CD3 + cells) infiltration in the tumors predicted survival. 
A high CD3 + value predicted a decreased survival. This 
was valid concerning recurrence (p = 0.017) and DSS 
(p = 0.032), but not for OS (Fig. 6).
Discussion
High IL-6 and IL-27 serum levels predicted a worse 
prognosis. Among clinically presumed radically treated 
patients, a high IL-6 and high IL-27 strongly predicted a 
recurrence in both univariate and multivariate analyses. IL-6 
also predicted DSS and OS. Overall, the predictions among 
patients with large tumors (diameter > 7 cm) were excellent 
regarding both high IL-6 and IL-27 values. Of the soluble 
receptors studied, high gp130 serum levels predicted a worse 
OS among the RCC patients with large tumors.
The cytokine levels best predicted survival among 
patients with large tumors. These findings support that 
a high cytokine value points to a biologically aggressive 
tumor, more than a low differentiated tumor [8, 10, 24].
Patients with high levels of IL-6, but only with a 
clinically localized disease, were more likely to die from 
their RCC, and also had an increased risk of dying of any 
cause compared to those with low IL-6 serum values. Our 
findings are in agreement with those of Ljungberg et al. [25], 
Hrab et al. [26] and Blay et al. [27].
Increased IL-27 levels predicted recurrence and DSS, 
especially among patients with a tumor diameter > 7 cm. 
To the best of our knowledge, this has not been shown in 
other published studies. Only one study has thus far been 
published on IL-27 and RCC, which showed that patients 
with specific polymorphisms of IL-27 are more susceptible 
to RCC [17].
Soluble IL-6Rα may bind to IL-6, and secondarily bind 
to gp130 receptors on the surface of cells, in this way 
stimulating pro-inflammatory functions through trans-
activation. On the other hand, cis-activation is mostly 
immune inhibitory [28]. We have not shown negative 
prognostic effects of increased serum IL-6Rα among RCC 
patients, supporting that IL-6 promotes inflammation in 
RCC tumors as a mechanism of IL-6-driven carcinogenesis. 
Soluble gp130 binds the soluble IL-6/IL-6Rα complex [29], 
and presumably acts as an IL-6/IL-6Rα decoy receptor 
[28]. We have demonstrated a negative prognostic value of 
increased gp130 in the serum of patients with larger tumors, 
which is the opposite of what should be expected. However, 
gp130 is present on most cells [28], and the increased serum 
soluble gp130 may be caused by generally increased tumor 
cellular turnover, which then basically drives the worse 
prognosis.
The combined effect of soluble IL-6Rα, gp130 and 
IL-6 as to prognosis seems to be complex. Regarding 
small tumors, the results are as expected, but concerning 
larger tumors s-gp130 levels paint another picture more 
consistent with that reflected by s-gp130 levels, e.g., cellular 
proliferation. Furthermore, the similar survival prediction 
of IL-6 and IL-27 suggests that this association is limited to 
cells actually carrying the IL-6 receptor on the surface, as no 
soluble IL-27 receptor has so far been recognized.
IL-6 and the IL6R may also be determined in tumor tissue 
[20]. Fu et al. [20] have shown that the expression on tumor 
cells of IL-6/IL6R worsens the prognosis. We have verified 
that both the IL-6 and IL6R may be found on cancer cells 
from RCC patients with high IL-6. Hence, it is supported 
that IL-6 may act directly on the tumor with a subsequent 
Fig. 6  Outcome predictions: a recurrence, b disease-specific 
survival, and c overall survival of total 28 RCC patients from 
immunohistochemical quantification of tumor CD3-positive T 
lymphocytes in surgical resection specimen. The expression levels 
were qualitatively scored by an experienced pathologist and further 
dichotomized by median value into high (All patients: n = 11/radically 
treated: n = 8) and low (n = 17 for all patients/n = 14 for radically 
treated). p values come from log-rank tests
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worse RCC prognosis, both in an autocrine and paracrine 
manner [30].
We have also shown that among patients with a high IL-6, 
a surprisingly high expression of IL-6 was found in vascular 
cells, i.e., endothelial and smooth muscle cells, thereby 
suggesting that these cells produce IL-6. Endothelial cells 
are presumably stimulated by VEGF from the tumor [31], 
with this representing a possible loop where the tumor may 
become autocrine stimulated.
High IL-6 values in serum also signal a worse OS, and 
as such, IL-6 values are coupled with many serious diseases 
[32]. IL-6 is elevated in hypertension, as well as being 
associated with a higher incidence of future cardiovascular 
events and mortality [33]. This may partly explain the shown 
overall survival prediction.
Moreover, we have studied levels of T lymphocyte tumor 
infiltration and presence in the tumor periphery in a sub-
group of patients selected by high IL-6 serum levels. A high 
T lymphocyte count predicted an increased recurrence and 
decreased survival. Nevertheless, T regulatory lymphocytes, 
i.e., Fox P3 lymphocytes, were not to any extent found 
within the tumor. This is in line with what has previously 
been shown in head and neck squamous cell carcinomas 
[34], namely that survival prediction in solid tumors is 
likely dependent on several immune-related dimensions, like 
presently one associated with general inflammation through 
IL-6, and another associated with specific immunity though 
T lymphocytes [35].
RCC survival prediction is expected to be secondary 
to factors like the ones included in the Leibovich scores. 
Leibovich is a composite score, including tumor size, 
pathological T and N stage, Fuhrman nuclear grading 
and histological necrosis [36]. With the IL-6 and IL-27 
recurrence prediction adjusted by the Leibovich score, both 
of these cytokine levels still predicted survival.
Clinically, the present results may be relevant. When 
applying 8 pg/ml IL-6 levels as a cut-off between high and 
low IL-6 values, 29 patients had high IL-6 values. Six out 
of nine patients with detectable metastasis at diagnosis 
had high IL-6 values, as had seven of 14 individuals who 
subsequently developed RCC metastases. Several other 
patients presumably had other specific causes of their 
increased IL-6. Of those patients with a low IL-6 who died, 
or developed recurrent RCC disease (n = 10) only one had 
a RCC tumor with a diameter < 7 cm at diagnosis. The IL-6 
values may therefore be utilized at the individual level to 
sort patients with both a high and low risk of dying because 
of RCC disease.
Furthermore, ROC analyses suggested that a high IL-27 
and IL-6 score predicted a recurrence with both a high 
sensitivity and specificity, especially as measured in patients 
with larger tumors. Thus, we have demonstrated that IL-6 
and IL-27 may be utilized as biomarkers to identify both a 
high- and low-risk recurrence of RCC patients at the time 
of diagnosis.
Patients with high IL-6/IL-27 values at diagnosis may 
be good candidates for adjuvant treatment with, e.g., VEGF 
inhibitors [37], as well as with anti-IL-6 therapy such as 
Siltuximab [38]. The agent Siltuximab (αIL-6) has shown 
promising results in phase I/II studies for metastatic RCC 
[38]. It is even possible that a combined blockage of IL-6/
IL-27/VEGF would have achieved better results. The 
results of our study also demonstrate the need for future 
clinical studies of therapies investigating blockage of 
gp130 pathways, i.e., bazedoxifene, which blocks p-STAT3 
inhibitor [39], and also combined with other blockers like 
VEGF-TKIs [40] to prolong survival in patients with RCC 
[41]. However, it should be borne in mind that babies born 
with a defect gp130 receptor may suffer from extended 
Stüve-Wiedemann syndrome, which is a serious, often lethal 
syndrome [42]. Thus, to block gp130 may have serious side 
effects, making such treatment impossible. Our results also 
add to knowledge inspiring T cell boosting therapy to be 
further developed. In any case, the role of IL-27 biology in 
RCC should be studied judged against the background that 
new templates for biological therapy in RCC therapy are 
urgently needed [43].
This study includes a limited number of patients. 
Therefore, the analyses, especially on the sub-group level 
showing negative results, must be interpreted with caution. 
We have measured the cytokines and soluble receptor levels 
just once. In particular, cytokines in the blood may have a 
short half-life [44], as a broader picture could have been 
painted with additional measuring points.
Conclusions
IL-6 and IL-27 have been shown to have a role in RCC 
biology through the predictive ability of recurrence and 
disease-specific survival in otherwise radically treated 
RCC patients. We believe that patients with a high IL-6 and 
IL-27 will be good candidates on which to base a biological 
therapy of RCC. Finally, both these cytokines hold promise 
for being important in relation to risk stratification regarding 
RCC prognosis, and thereby a need for treatment.
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